The 9.4T animal magnetic resonance imaging system is optimised for high-resolution sample imaging.
The Biomarker Discovery Platform provides infrastructure for the detection and quantification of biomarkers, such as proteins, peptides and nucleotides, in any biological fluids and samples.
Harnessing RNA therapeutics and LNP technologies to facilitate CRISPR gene editing in preclinical models.
Harnessing the transformative power of mRNA-based therapies to address the global burden of cardiometabolic diseases.
Magnetic Particle Imaging (MPI) is a new non-invasive imaging method that detects iron oxide nanoparticles to produce 2D and 3D images. MPI imaging is more sensitive and significantly faster than MRI and PET imaging.
The Metabolomics (lipidomic) Profiling Facility uses state-of-the-art tandem mass spectrometry to obtain metabolic profiles (primarily lipids) from cell and animal models.
The Microscopy Centre enables researchers to perform leading-edge microscopy to advance the treatment of cardiovascular disease, diabetes, and related disorders.
The Mediso NanoPET/CT is a small animal preclinical scanner suitable for a wide variety of radioactive tracer imaging and computer tomography (CT).
The Translational Cardiology Centre team are leaders in clinical assessments of animal models for trials of new medicines.
The Proteomics Research Platform develops and applies advanced proteomics methods to further our understanding of cardiac disease, pathways, targets, and drug effects.
The Single-Cell Omics Platform applies single-cell omic approaches to understand complex tissues in context of development and disease.
You can play an essential role in our research
With the rising number of Australians affected by diabetes, heart disease and stroke, the need for research is more critical than ever.
